Translating TRAIL-receptor targeting agents to the clinic

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 194-201

  den Hollander, Martha W ^a   Gietema, Jourik A ^a   de Jong, Steven ^a   Walenkamp, Annemiek M E ^a   Reyners, Anna K L ^a   Oldenhuis, Corina N A M ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Biomarkers; Clinical studies; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CONATUMUMAB; DOXORUBICIN; DROZITUMAB; DULANERMIN; FLUOROURACIL; FOLINIC ACID; GANITUMAB; GEMCITABINE; IRINOTECAN; LBY 135; LEXATUMUMAB; MAPATUMUMAB; PACLITAXEL; PANITUMUMAB; PLACEBO; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; SORAFENIB; TIGATUZUMAB; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; AMYLASE BLOOD LEVEL; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHONDROSARCOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; HODGKIN DISEASE; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; SARCOMA; SEPTICEMIA; SHORT SURVEY; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER;

EID: 84876078450     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.007     Document Type: Review

References (73)

1. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
2. Rus V., Nguyen V., Puliaev R., Puliaeva I., Zernetkina V., Luzina I., Papadimitriou J.C., Via C.S. T cell TRAIL promotes murine lupus by sustaining effector CD4 th cell numbers and by inhibiting CD8 CTL activity. J. Immunol. 2007, 178:3962-3972.
3. Hoffmann O., Priller J., Prozorovski T., Schulze-Topphoff U., Baeva N., Lunemann J.D., Aktas O., Mahrhofer C., Stricker S., Zipp F., Weber J.R. TRAIL limits excessive host immune responses in bacterial meningitis. J. Clin. Invest. 2007, 117:2004-2013.
4. Finnberg N., Klein-Szanto A.J., El-Deiry W.S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 2008, 118:111-123.
5. Spierings D.C., de Vries E.G., Vellenga E., van den Heuvel F.A., Koornstra J.J., Wesseling J., Hollema H., de Jong S. Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem. 2004, 52:821-831.
6. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999, 104:155-162.
7. Duiker E.W., Mom C.H., de Jong S., Willemse P.H., Gietema J.A., van der Zee A.G., de Vries E.G. The clinical trail of TRAIL. Eur. J. Cancer 2006, 42:2233-2240.
8. Chuntharapai A., Dodge K., Grimmer K., Schroeder K., Marsters S.A., Koeppen H., Ashkenazi A., Kim K.J. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 2001, 166:4891-4898.
9. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., Zhang H., Mountz J.D., Koopman W.J., Kimberly R.P., Zhou T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 2001, 7:954-960.
10. Jin H., Yang R., Ross J., Fong S., Carano R., Totpal K., Lawrence D., Zheng Z., Koeppen H., Stern H., Schwall R., Ashkenazi A. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin. Cancer Res. 2008, 14:7733-7740.
11. Luster T.A., Carrell J.A., McCormick K., Sun D., Humphreys R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol. Cancer. Ther. 2009, 8:292-302.
12. Marini P., Junginger D., Stickl S., Budach W., Niyazi M., Belka C. Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions. Radiat. Oncol. 2009, 4:49.
13. Herbst R.S., Eckhardt S.G., Kurzrock R., Ebbinghaus S., O'Dwyer P.J., Gordon M.S., Novotny W., Goldwasser M.A., Tohnya T.M., Lum B.L., Ashkenazi A., Jubb A.M., Mendelson D.S. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 2010, 28:2839-2846.
14. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., Hill M., Mays T., McCoy T., Fox N.L., Halpern W., Corey A., Cohen R.B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 2007, 25:1390-1395.
15. Hotte S.J., Hirte H.W., Chen E.X., Siu L.L., Le L.H., Corey A., Iacobucci A., MacLean M., Lo L., Fox N.L., Oza A.M. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res. 2008, 14:3450-3455.
16. Trarbach T., Moehler M., Heinemann V., Kohne C.H., Przyborek M., Schulz C., Sneller V., Gallant G., Kanzler S. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer 2010, 102:506-512.
17. Greco F.A., Bonomi P., Crawford J., Kelly K., Oh Y., Halpern W., Lo L., Gallant G., Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008, 61:82-90.
18. Younes A., Vose J.M., Zelenetz A.D., Smith M.R., Burris H.A., Ansell S.M., Klein J., Halpern W., Miceli R., Kumm E., Fox N.L., Czuczman M.S. A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br. J. Cancer 2010, 103:1783-1787.
19. Plummer R., Attard G., Pacey S., Li L., Razak A., Perrett R., Barrett M., Judson I., Kaye S., Fox N.L., Halpern W., Corey A., Calvert H., de Bono J. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 2007, 13:6187-6194.
20. Wakelee H.A., Patnaik A., Sikic B.I., Mita M., Fox N.L., Miceli R., Ullrich S.J., Fisher G.A., Tolcher A.W. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann. Oncol. 2010, 21:376-381.
21. Merchant M.S., Chou A.J., Price A., Geller J.I., Tsokos M., Graham C., Charles A., Meyers P.A., Mackall C. Lexatumumab: results of a phase I trial in pediatric patients with advanced solid tumors. J. Clin. Oncol. 2010, 28(15s). (Suppl. Abstr. 9500).
22. Camidge D.R., Herbst R.S., Gordon M.S., Eckhardt S.G., Kurzrock R., Durbin B., Ing J., Tohnya T.M., Sager J., Ashkenazi A., Bray G., Mendelson D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin. Cancer Res. 2010, 16:1256-1263.
23. Forero-Torres A., Shah J., Wood T., Posey J., Carlisle R., Copigneaux C., Luo F.R., Wojtowicz-Praga S., Percent I., Saleh M. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother. Radiopharm. 2010, 25:13-19.
24. Herbst R.S., Kurzrock R., Hong D.S., Valdivieso M., Hsu C.P., Goyal L., Juan G., Hwang Y.C., Wong S., Hill J.S., Friberg G., LoRusso P.M. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin. Cancer Res. 2010, 16:5883-5891.
25. Doi T., Murakami H., Ohtsu A., Fuse N., Yoshino T., Yamamoto N., Boku N., Onozawa Y., Hsu C.P., Gorski K.S., Friberg G., Kawaguchi T., Sasaki T. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2011, 68:733-741.
26. S. Sharma, E.G. de Vries, J.R. Infante, C. Oldenhuis, L. Chiang, S. Bilic, M. Goldbrunner, J.W. Scott, H.A. Burris III, Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors, J. Clin. Oncol. 26 (2008) (Suppl. Abstr. 3538).
27. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 2000, 6:564-567.
28. Mahalingam D., Szegezdi E., Keane M., de Jong S., Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat. Rev. 2009, 35:280-288.
29. Ricci M.S., Kim S.H., Ogi K., Plastaras J.P., Ling J., Wang W., Jin Z., Liu Y.Y., Dicker D.T., Chiao P.J., Flaherty K.T., Smith C.D., El-Deiry W.S. Reduction of TRAIL-induced mcl-1 and cIAP2 by c-myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007, 12:66-80.
30. Daniel D., Yang B., Lawrence D.A., Totpal K., Balter I., Lee W.P., Gogineni A., Cole M.J., Yee S.F., Ross S., Ashkenazi A. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-hodgkin lymphoma xenografts. Blood 2007, 110:4037-4046.
31. Soria J.C., Smit E., Khayat D., Besse B., Yang X., Hsu C.P., Reese D., Wiezorek J., Blackhall F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1527-1533.
32. Soria J.C., Márk Z., Zatloukal P., Szima B., Albert I., Juhász E., Pujol J.L., Kozielski J., Baker N., Smethurst D., Hei Y.J., Ashkenazi A., Stern H., Amler L., Pan Y., Blackhall F. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:4442-4451.
33. Fanale M., Burris H., Yee L., Lucas J., Dimick K., Goldwasser M., Novotny W., Bray G. Results of a phase 1B study of recombinant human APO2L/TRAIL with rituximab in patietns with relapsed low-grade NHL. Ann. Oncol. 2008, 19:161.
34. D. Belada, J. Mayer, M.S. Czuczman, I.W. Flinn, B. Durbin-Johnson, G.L. Bray, Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL), J. Clin. Oncol. 28(15s) (2010) (Suppl. Abstr. 8104).
35. L. Yee, H.A. Burris, M. Kozloff, Z. Wainberg, M. Pao, S. Skettino, W. Novotny, B. Durbin, J. Weston, H. Hurwitz, Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): preliminary results, J. Clin. Oncol. 27(15s) (2009) (Suppl. Abstr. 4129).
36. Mom C.H., Verweij J., Oldenhuis C.N., Gietema J.A., Fox N.L., Miceli R., Eskens F.A., Loos W.J., de Vries E.G., Sleijfer S. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin. Cancer Res. 2009, 15:5584-5590.
37. Leong S., Cohen R.B., Gustafson D.L., Langer C.J., Camidge D.R., Padavic K., Gore L., Smith M., Chow L.Q., von Mehren M., O'Bryant C., Hariharan S., Diab S., Fox N.L., Miceli R., Eckhardt S.G. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J. Clin. Oncol. 2009, 27:4413-4421.
38. J. Von Pawel, J.H. Harvey, D.R. Spigel, M. Dediu, M. Reck, C.L. Cebotaru, E. Kumm, G. Gallant, N. Fox, D.R. Camidge, A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC, J. Clin. Oncol. 28(18s) (2010) (Suppl. Abstr. LBA7501).
39. W. Sun, D. Nelson, S.R. Alberts, F. Poordad, S. Leong, U.R. Teitelbaum, L. Woods, N. Fox, B.H. O'Neil, Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis, J. Clin. Oncol. 29 (2011) (Suppl. Abstr. 261).
40. B.I. Sikic, H.A. Wakelee, M. von Mehren, N. Lewis, A.H. Calvert, E.R. Plummer, N.L. Fox, T. Howard, S.F. Jones, H.A. Burris III, A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI, J. Clin. Oncol. 25(18s) (2007) (Suppl. Abstr. 14006).
41. C.S. Karapetis, P.R. Clingan, N.B. Leighl, B. Durbin-Johnson, V. O'Neill, D.R. Spigel, Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC), J. Clin. Oncol. 28(15s) (2010) (Suppl. Abstr. 7535).
42. S. Wittebol, A. Ferrant, N.W. Wickham, L. Fehrenbacher, B. Durbin-Johnson, G.L. Bray, Phase II study of PRO95780 plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL), J. Clin. Oncol. 28 (2010) (Suppl. Abstr. e18511).
43. C.S. Rocha Lima, J.C. Baranda, J. Wallmark, Y. Choi, S. Royer-Joo, C.C. Portera, Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC), J. Clin. Oncol. 29 (2011) (Suppl. Abstr. 546).
44. A.D. Baron, C.L. O'Bryant, Y. Choi, A. Ashkenazi, S. Royer-Joo, C.C. Portera, Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC), J. Clin. Oncol. 29 (2011) (Suppl. Abstr. 3581).
45. L. Paz-Ares, J.M. Sanchez Torres, I. Diaz-Padilla, M. Links, N. Reguart, M. Boyer, J. Wiezorek, T. Sabin, Y. Pan, J. Van Meerbeeck, Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC), J. Clin. Oncol. 27 (2009) (Suppl. Abstr. e19048).
46. L. Saltz, J. Infante, L. Schwartzberg, J. Stephenson, C. Rocha-Lima, F. Galimi, K. Dillingham, M. Hsu, J. Wiezorek, C. Fuchs, Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC), J. Clin. Oncol. 27(15s) (2009) (Suppl. Abstr. 4079).
47. H.L. Kindler, L. Garbo, J. Stephenson, J. Wiezorek, T. Sabin, M. Hsu, F. Civoli, D. Richards, A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC), J. Clin. Oncol. 27(15s) (2009) (Suppl. Abstr. 4501).
48. M. Peeters, J.R. Infante, P. Rougier, J. Van Laethem, H.E. Uronis, J. Stephenson, L. S. Schwartzberg, L. Chen, D. Smethurst; Phase Ib/II trial of conatumumab and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): safety and efficacy, ASCO Gastrointest. Cancers Symp. Abstract 443 (2010).
49. S.P. Chawla, J. Tabernero, H.L. Kindler, E.G. Chiorean, P. LoRusso, M. Hsu, V. Haddad, B.A. Bach, J. Baselga, Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors. J. Clin. Oncol. 28(15s) (2010) (Suppl. Abstr. 3102).
50. H.L. Kindler, D.A. Richards, J. Stephenson, L.E. Garbo, C.S. Rocha Lima, H. Safran, J. S. Wiezorek, E.G. Feigal, S. Bray, C. Fuchs, A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC), J. Clin. Oncol. 28(15s) (2010) (Suppl. Abstr. 4035).
51. Demetri G.D., Le Cesne A., Chawla S.P., Brodowicz T., Maki R.G., Bach B.A., Smethurst D.P., Bray S., Hei Y.J., Blay J.Y. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur. J. Cancer 2012, 48:547-563.
52. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., Erdkamp F.L., Vos A.H., van Groeningen C.J., Sinnige H.A., Richel D.J., Voest E.E., Dijkstra J.R., Vink-Börger M.E., Antonini N.F., Mol L., van Krieken J.H., Dalesio O., Punt C.J. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:563-572.
53. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J., Cohn A., McCollum D., Stella P., Deeter R., Shahin S., Amado R.G. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:672-680.
54. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
55. T. Griffith, B. Konety, F. Joudi, H. Aubert, M. Cohen, T. Ratliff, R. Williams, Phase I study of Ad5-TRAIL in men with clinically organ confined prostate cancer, Am. Assoc. Cancer Res. Proc. (2007) 4870.
56. Wajant H., Moosmayer D., Wuest T., Bartke T., Gerlach E., Schonherr U., Peters N., Scheurich P., Pfizenmaier K. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001, 20:4101-4106.
57. Bremer E., Samplonius D.F., van Genne L., Dijkstra M.H., Kroesen B.J., de Leij L.F., Helfrich W. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:STRAIL fusion protein with specificity for human EGFR. J. Biol. Chem. 2005, 280:10025-10033.
58. ten Cate B., Bremer E., de Bruyn M., Bijma T., Samplonius D., Schwemmlein M., Huls G., Fey G., Helfrich W. A novel AML-selective TRAIL fusion protein that is superior to gemtuzumab ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009, 23:1389-1397.
59. Bremer E., Samplonius D.F., Peipp M., van Genne L., Kroesen B.J., Fey G.H., Gramatzki M., de Leij L.F., Helfrich W. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res. 2005, 65:3380-3388.
60. van der Sloot A.M., Tur V., Szegezdi E., Mullally M.M., Cool R.H., Samali A., Serrano L., Quax W.J. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl. Acad. Sci. USA 2006, 103:8634-8639.
61. Reis C.R., van der Sloot A.M., Natoni A., Szegezdi E., Setroikromo R., Meijer M., Sjollema K., Stricher F., Cool R.H., Samali A., Serrano L., Quax W.J. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell. Death Dis. 2010, 1:e83.
62. H. Huet, A. Schuller, J. Li, J. Johnson, B. Dombrecht, K. Meerschaert, K. Cromie, S. Bilic, S. Li, A. Garner, S. Nunes, R. Chopra, K. Clark, M. Yao, S. Fawell, D. Stover, W.R. Sellers, S. Ettenberg, TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches, Am. Assoc. Cancer Res. Proc. (2012) 3853.
63. Pan Y., Xu R., Peach M., Huang C.P., Branstetter D., Novotny W., Herbst R.S., Eckhardt S.G., Holland P.M. Evaluation of pharmacodynamic biomarkers in a phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br. J. Cancer 2011, 105:1830-1838.
64. Zoog S.J., Ma C.Y., Kaplan-Lefko P.J., Hawkins J.M., Moriguchi J., Zhou L., Pan Y., Hsu C.P., Friberg G., Herbst R., Hill J., Juan G. Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry A 2010, 77:849-860.
65. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
66. E.A. Punnoose, K. Wagner, L. Amler, A. Ashkenazi, Sensitivity to apomab, an agonistic DR5 specific antibody, is correlated with expression of specific O-glycosyl transferases in tumor-cell lines of both epithelial and non epithelial origin, Am. Assoc. Cancer Res. Proc. (2009) 687.
67. Stern H.M., Padilla M., Wagner K., Amler L., Ashkenazi A. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin. Cancer Res. 2010, 16:1587-1596.
68. Kim H., Chaudhuri T.R., Buchsbaum D.J., Wang D., Zinn K.R. High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol. Cancer. Ther. 2007, 6:866-875.
69. Gong J., Yang D., Kohanim S., Humphreys R., Broemeling L., Kurzrock R. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol. Cancer. Ther. 2006, 5:2991-3000.
70. L. Zhou, D. Dicker, W. Wang, W.S. El-Deiry, Prediction of pro-apoptotic anti-cancer therapeutic response by visualization of death receptors and specific markers of apoptosis, Am. Assoc. Cancer Res. Proc. (2009) 4471.
71. Rossin R., Kohno T., Hagooly A., Sharp T., Gliniak B., Arroll T., Chen Q., Hewig A., Kaplan-Lefko P., Friberg G., Radinsky R., Evelhoch J.L., Welch M.J., Hwang D.R. Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5. J. Nucl. Med. 2011, 52:942-949.
72. Duiker E., Dijkers E., Heerspink H.L., de Jong S., van der Zee A., Jager P., Kosterink J., de Vries E., Hooge M.L. Development of radioiodinated rhTRAIL and a radiolabelled agonistic TRAIL receptor antibody for clinical imaging studies. Br. J. Pharmacol. 2012, 165:2203-2212.
73. C. Oldenhuis, E.C. Dijkers, E.W. Duiker, N.L. Fox, J.L. Klein, J.A. Gietema, A.H. Brouwers, M.N. Lub-de Hooge, E.G. de Vries, Development of radiolabeled mapatumumab and imaging in solid tumor patients who are treated with gemcitabine, cisplatin, and mapatumumab, J. Clin. Oncol. 27 (2009) (Suppl. Abstr. e14521).